Market Analysis and Price Projections for NDC 70000-0243: Leader Urinary Pain Relief
Overview of NDC 70000-0243
NDC 70000-0243 corresponds to Leader Urinary Pain Relief, a non-prescription (OTC) drug containing the active ingredient Phenazopyridine Hydrochloride. This drug is used to alleviate urinary tract pain and is marketed by Cardinal Health[1].
Market Context
OTC Drug Market
The OTC drug market is characterized by a wide range of products addressing various common health issues. Urinary pain relief drugs, like Leader Urinary Pain Relief, are part of this broader market. The demand for these products is generally stable, driven by the frequent occurrence of urinary tract infections and other urinary issues.
Competitive Landscape
The market for urinary pain relief drugs is competitive, with several brands offering similar products. The competition is based on factors such as efficacy, price, brand recognition, and distribution channels. Leader Urinary Pain Relief competes with other phenazopyridine-based products and alternative treatments.
Pricing Dynamics
Current Pricing
As an OTC drug, the pricing of Leader Urinary Pain Relief is not subject to the same level of regulatory scrutiny as prescription drugs. However, prices are influenced by market forces, including competition and consumer demand. The current price of Leader Urinary Pain Relief is determined by Cardinal Health and can vary depending on the retailer and location.
Price Stability
Unlike many prescription drugs, OTC drugs tend to have more stable prices due to their widespread availability and competition. However, prices can still fluctuate based on production costs, raw material prices, and market conditions.
Regulatory Environment
FDA Oversight
The FDA regulates OTC drugs, including Leader Urinary Pain Relief, through the National Drug Code (NDC) system. The NDC Directory ensures that all drugs, including OTC products, are properly listed and monitored[4].
Compliance and Labeling
Leader Urinary Pain Relief must comply with FDA regulations regarding labeling, packaging, and marketing. Any changes in regulatory requirements can impact the product's pricing and availability.
Market Projections
Demand Forecast
The demand for urinary pain relief drugs is expected to remain steady due to the ongoing need for these products. However, there may be slight variations based on seasonal factors (e.g., increased urinary tract infections during certain times of the year) and demographic changes.
Price Projections
Given the stable nature of the OTC market, significant price increases for Leader Urinary Pain Relief are unlikely. Here are some key points to consider:
- Stable Pricing: The price of Leader Urinary Pain Relief is expected to remain relatively stable, with minor adjustments based on production costs and market conditions.
- Competitive Pressure: The competitive landscape may lead to slight price reductions if other brands offer similar products at lower prices.
- Regulatory Impact: Any changes in FDA regulations or labeling requirements could influence pricing, but this is less likely for established OTC products.
Key Takeaways
- Stable Demand: The demand for urinary pain relief drugs is expected to remain steady.
- Competitive Pricing: Prices will be influenced by competition within the OTC market.
- Regulatory Compliance: Adherence to FDA regulations is crucial for maintaining market presence.
- Minor Price Adjustments: Prices may see minor adjustments based on production costs and market conditions.
FAQs
Q: What is the active ingredient in Leader Urinary Pain Relief?
A: The active ingredient is Phenazopyridine Hydrochloride[1].
Q: Who is the labeler for Leader Urinary Pain Relief?
A: The labeler is Cardinal Health[1].
Q: Is Leader Urinary Pain Relief a prescription drug?
A: No, it is an over-the-counter (OTC) drug[1].
Q: How is the pricing of Leader Urinary Pain Relief determined?
A: Pricing is determined by Cardinal Health and influenced by market forces such as competition and consumer demand.
Q: Are there any regulatory changes that could impact the pricing of Leader Urinary Pain Relief?
A: Significant regulatory changes are unlikely, but any changes in FDA regulations could influence pricing and availability[4].
Sources
- FDA Report: NDC 70000-0243 Oral Tablet Leader Urinary Pain Relief Drug.
- ASPE - HHS.gov: Medicare Drug Price Negotiation Program.
- GlobalData: NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025.
- FDA: National Drug Code Directory.
